AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32507672 — intervention group
Group type: EXPERIMENTAL
Intervention: istiratumab (MM-141) plus nab-paclitaxel and gemcitabine
Number of subjects: 0
Study 32507672 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel and gemcitabine
Number of subjects: 0
Study 35929973 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational treatment arm
Number of subjects: 0
Study 35929973 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 32439266 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d of GAA for 4 weeks
Number of subjects: 19
Study 32513317 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-squared crackers with cheese dip
Number of subjects: 44
Study 32513317 — intervention group
Group type: COMPARATOR
Intervention: Finger-shape crackers with cheese dip
Number of subjects: 44
Study 32513317 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-squared crackers
Number of subjects: 44
Study 32513317 — intervention group
Group type: COMPARATOR
Intervention: Finger-shape crackers
Number of subjects: 44
Study 32513317 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cracker intake
Number of subjects: 44
Study 34289222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine 200 mg once a day for 3 months
Number of subjects: 113
Study 34289222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 32749193 — intervention group
Group type: EXPERIMENTAL
Intervention: WFIRS-P (Weiss Functional Impairment Rating Scale - Parent report)
Number of subjects: 102
Study 32749193 — intervention group
Group type: EXPERIMENTAL
Intervention: WFIRS-S (Weiss Functional Impairment Rating Scale - Self report)
Number of subjects: 102
Study 35987956 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (FloraVantage®)
Number of subjects: 31
Study 35987956 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 31
Study 35654564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush/Rinse (BR)
Number of subjects: 209
Study 35654564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush/Floss/Rinse (BFR)
Number of subjects: 209
Study 35654564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush/Floss (BF)
Number of subjects: 209
Study 35654564 — intervention group
Group type: COMPARATOR
Intervention: Brush Only (BO)
Number of subjects: 209
Study 35831045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pravastatin
Number of subjects: 0
Study 35831045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33026710 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention for chronic pain
Number of subjects: 517
Study 32650673 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for vulvodynia
Number of subjects: 48
Study 32650673 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 36175126 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled surgical trials (RPCTs)
Number of subjects: 687
Study 34192922 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous (IV) tranexamic acid (TXA) at the time of surgery and an additional oral regime for 24 hours postoperatively
Number of subjects: 534
Study 34192922 — intervention group
Group type: COMPARATOR
Intervention: Only intraoperative dose of TXA
Number of subjects: 534
Study 34192922 — intervention group
Group type: COMPARATOR
Intervention: No TXA
Number of subjects: 534
Study 32549724 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with OVDs (OVD group)
Number of subjects: 220
Study 32549724 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification without OVDs (BSS group)
Number of subjects: 220
Study 34011463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (43 patients)
Number of subjects: 85
Study 34011463 — intervention group
Group type: COMPARATOR
Intervention: Microsuture (42 patients)
Number of subjects: 85
Study 34056967 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS) at 2 mA for 20 minutes over the left dorsolateral prefrontal cortex the day after each match.
Number of subjects: 13
Study 34056967 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 13
Study 34056967 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS) combined with recovery training session.
Number of subjects: 13
Study 35477178 — intervention group
Group type: EXPERIMENTAL
Intervention: PAGGGM
Number of subjects: 20
Study 35477178 — intervention group
Group type: COMPARATOR
Intervention: SAGM
Number of subjects: 20
Study 34565444 — intervention group
Group type: EXPERIMENTAL
Intervention: TACUNA intervention (three virtual workshops utilizing motivational interviewing, social network visualization, and integrating traditional practices and a wellness circle)
Number of subjects: 370
Study 34565444 — intervention group
Group type: COMPARATOR
Intervention: Culturally sensitive opioid education workshop (control group)
Number of subjects: 370
Study 34565444 — intervention group
Group type: EXPERIMENTAL
Intervention: TACUNA intervention
Number of subjects: 370
Study 35317789 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Treatment (AT), n=250, consisting of a fully-automated smartphone-based intervention with 10 weeks of nicotine replacement therapy (NRT) including transdermal patches and lozenges.
Number of subjects: 500
Study 35317789 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST), n=250, connected to the Florida Quitline for telephone-based treatment and receiving a 10-week supply of nicotine replacement therapy (NRT).
Number of subjects: 500
Study 32437501 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed targeted intraoperative radiotherapy
Number of subjects: 0
Study 32437501 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast radiotherapy
Number of subjects: 0
Study 36228777 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication first arm (n = 226)
Number of subjects: 453
Study 36228777 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy first arm (n = 227)
Number of subjects: 453
Study 32940393 — intervention group
Group type: EXPERIMENTAL
Intervention: Life History Calendar (LHC)
Number of subjects: 1000
Study 32940393 — intervention group
Group type: COMPARATOR
Intervention: Retrospective diagnostic interview without LHC
Number of subjects: 1000
Study 32453139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg
Number of subjects: 0
Study 32453139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 0
Study 32453139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32453139 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 0
Study 35196954 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) applied before and after anastomosis (n = 12)
Number of subjects: 22
Study 35196954 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10) without RIC
Number of subjects: 22
Study 34089546 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25–50 mg) with a guided sleep phase advance
Number of subjects: 15
Study 32196772 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL)
Number of subjects: 54
Study 32196772 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid nanoemulsion (BF-200 ALA)
Number of subjects: 54
Study 32196772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexyl aminolevulinate (HAL)
Number of subjects: 54
Study 82282326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 250 to 300 mg/d
Number of subjects: 53
Study 82282326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 500 to 600 mg/d
Number of subjects: 53
Study 82282326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 900 to 1000 mg/d
Number of subjects: 53
Study 82282326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 10 to 12 mg/kg body weight
Number of subjects: 53
Study 82282326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (all doses)
Number of subjects: 53
Study 36075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted ferritin
Number of subjects: 400
Study 36075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cut-off (HC) ferritin
Number of subjects: 400
Study 36075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Thurnham-corrected (TC) ferritin
Number of subjects: 400
Study 36075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression-corrected (RC) ferritin
Number of subjects: 400
Study 36075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline elevated iron status (HC ferritin)
Number of subjects: 400
Study 32396205 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 172
Study 32396205 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 172
Study 36107505 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric-boswellia formulation (TBF) 1000 mg
Number of subjects: 232
Study 36107505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 36241767 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT)
Number of subjects: 65
Study 36241767 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory Strategy Training (CST)
Number of subjects: 65
Study 36241767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 36241767 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (APT, CST, Control)
Number of subjects: 65
Study 36241767 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Impact Assessment (FIA)
Number of subjects: 65
Study 36241767 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological total mean T‐score
Number of subjects: 65
Study 36241767 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-COG-PCI
Number of subjects: 65
Study 33025648 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg KLH immunization
Number of subjects: 15
Study 33025648 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg KLH intradermal administration after immunization
Number of subjects: 15
Study 33025648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 32342883 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVE training program
Number of subjects: 0
Study 32342883 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35465983 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later (Group 1)
Number of subjects: 149
Study 35465983 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of H7N9 IIV at three-week intervals after IIV4 alone (Group 2)
Number of subjects: 149
Study 35465983 — intervention group
Group type: COMPARATOR
Intervention: One dose of IIV4 (Group 3)
Number of subjects: 149
Study 33856155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberglass prosthetic foot
Number of subjects: 10
Study 33856155 — intervention group
Group type: COMPARATOR
Intervention: Carbon fiber prosthetic foot
Number of subjects: 10
Study 35271306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 824
Study 35271306 — intervention group
Group type: COMPARATOR
Intervention: No bortezomib (Control)
Number of subjects: 824
Study 32661703 — intervention group
Group type: COMPARATOR
Intervention: 2 mA tDCS
Number of subjects: 31
Study 32661703 — intervention group
Group type: COMPARATOR
Intervention: 1 mA tDCS
Number of subjects: 31
Study 32661703 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antisaccade task and tDCS
Number of subjects: 31
Study 32661703 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 31
Study 32921090 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-heating calf sleeves (SHCSs)
Number of subjects: 557
Study 32921090 — intervention group
Group type: COMPARATOR
Intervention: Control (no SHCSs)
Number of subjects: 557
Study 34669059 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg/day)
Number of subjects: 91
Study 34669059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 33162270 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aids (DAs)
Number of subjects: 147
Study 33162270 — intervention group
Group type: COMPARATOR
Intervention: No Decision Aids (Control)
Number of subjects: 147
Study 33162270 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain self-efficacy
Number of subjects: 147
Study 32066654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing drinks
Number of subjects: 12
Study 32066654 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sweeteners (NNS) containing drinks
Number of subjects: 12
Study 32066654 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened water
Number of subjects: 12
Study 35241360 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter diet pills
Number of subjects: 33824
Study 33645377 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1 (0.413/0.050 mg/day E3/TMG)
Number of subjects: 35
Study 33645377 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2 (0.311/0.090 mg/day E3/TMG)
Number of subjects: 35
Study 33645377 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 3 (0.209/0.137 mg/day E3/TMG)
Number of subjects: 35
Study 33645377 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1
Number of subjects: 35
Study 33645377 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2
Number of subjects: 35
Study 36401492 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) initiated when modified GCS score reached 13
Number of subjects: 296
Study 36401492 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV) initiated when modified GCS score reached 15
Number of subjects: 296
Study 35698158 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week regimen containing bedaquiline, pretomanid, and linezolid (arm 1)
Number of subjects: 0
Study 35698158 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (arm 2)
Number of subjects: 0
Study 35698158 — intervention group
Group type: COMPARATOR
Intervention: Standard of care arm (36 to 96 weeks duration)
Number of subjects: 0
Study 32703562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density ventricular substrate mapping during sinus rhythm
Number of subjects: 10
Study 35869145 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib every day (Arm A)
Number of subjects: 51
Study 35869145 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib days 1–5, 8–19 each cycle (Arm B)
Number of subjects: 51
Study 35869145 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine alone (Arm C)
Number of subjects: 51
Study 35869145 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (Arm A)
Number of subjects: 51
Study 35869145 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (Arm B)
Number of subjects: 51
Study 35869145 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib-containing arms
Number of subjects: 51
Study 35869145 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 51
Study 33907099 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine 1,000 mg/m2; twice daily for 14 days with oxaliplatin 130 mg/m2 on day 1, every 21 days)
Number of subjects: 90
Study 33907099 — intervention group
Group type: COMPARATOR
Intervention: DX (capecitabine 1,000 mg/m2; twice daily for 14 days with docetaxel 75 mg/m2 on day 1, every 21 days)
Number of subjects: 90
Study 33907099 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 90
Study 33907099 — intervention group
Group type: COMPARATOR
Intervention: DX
Number of subjects: 90
Study 34857499 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Classroom Training (VCT)
Number of subjects: 72
Study 34857499 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-Face Training (FFT)
Number of subjects: 72
Study 32591007 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) for 39 weeks
Number of subjects: 108
Study 32591007 — intervention group
Group type: COMPARATOR
Intervention: Usual vocational services (UVS) for 39 weeks
Number of subjects: 108
Study 32591007 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 108
Study 32591007 — intervention group
Group type: COMPARATOR
Intervention: UVS
Number of subjects: 108
Study 35658487 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice a day
Number of subjects: 538
Study 35658487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 34196464 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted traits of heart rate variability (HRV) - RMSSD
Number of subjects: 0
Study 34196464 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted traits of heart rate variability (HRV) - pvRSA/HF
Number of subjects: 0
Study 34196464 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted traits of heart rate variability (HRV)
Number of subjects: 0
Study 32535786 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 0
Study 32535786 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 0
Study 34013747 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg body wt‐1)
Number of subjects: 14
Study 34013747 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + Acetaminophen (Caffeine 5 mg·kg body wt‐1 + Acetaminophen 1,500 mg)
Number of subjects: 14
Study 34013747 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,500 mg)
Number of subjects: 14
Study 35414203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based fatigue education and prescription program (FatigueUCope)
Number of subjects: 279
Study 35414203 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 279
Study 34582548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention with an energy-restricted Mediterranean diet plus physical activity (n = 190)
Number of subjects: 391
Study 34582548 — intervention group
Group type: COMPARATOR
Intervention: Nonrestrictive Mediterranean diet without physical activity (control; n = 201)
Number of subjects: 391
Study 34749997 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscing and Emotion Training (RET) intervention
Number of subjects: 137
Study 34749997 — intervention group
Group type: EXPERIMENTAL
Intervention: Family resources during the pandemic
Number of subjects: 137
Study 32189094 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine monitoring by an Advanced Nurse Practitioner (ANP)
Number of subjects: 173
Study 32189094 — intervention group
Group type: COMPARATOR
Intervention: Clozapine monitoring by a psychiatrist
Number of subjects: 173
Study 32189094 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine monitoring by an ANP
Number of subjects: 173
Study 34102418 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, 110% motor threshold, 1200 pulses/session) combined with daily gait training
Number of subjects: 58
Study 34102418 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS combined with daily gait training
Number of subjects: 58
Study 34102418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active and sham TMS groups
Number of subjects: 58
Study 32954301 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity neurofeedback training
Number of subjects: 32
Study 32954301 — intervention group
Group type: EXPERIMENTAL
Intervention: Connectivity neurofeedback training
Number of subjects: 32
Study 32954301 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 32
Study 36383362 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 + No. 10 group
Number of subjects: 536
Study 36383362 — intervention group
Group type: COMPARATOR
Intervention: D2 group
Number of subjects: 536
Study 36383362 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 + No. 10 group (advanced posterior gastric cancer)
Number of subjects: 536
Study 36383362 — intervention group
Group type: COMPARATOR
Intervention: D2 group (advanced posterior gastric cancer)
Number of subjects: 536
Study 33562699 — intervention group
Group type: EXPERIMENTAL
Intervention: Light–moderate walking outdoors (exercise condition)
Number of subjects: 23
Study 33562699 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition (sitting and reading)
Number of subjects: 23
Study 35197202 — intervention group
Group type: COMPARATOR
Intervention: CAC score of 781 (418–1467)
Number of subjects: 20207
Study 35197202 — intervention group
Group type: COMPARATOR
Intervention: CAC score of 255 (162–394)
Number of subjects: 20207
Study 33249244 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage group
Number of subjects: 80
Study 33249244 — intervention group
Group type: COMPARATOR
Intervention: Noncurettage group
Number of subjects: 80
Study 35617674 — intervention group
Group type: EXPERIMENTAL
Intervention: Me & You curriculum
Number of subjects: 10
Study 35617674 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 10
Study 34432985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 1719
Study 34432985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1719
Study 32114477 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) plus metformin
Number of subjects: 120
Study 35924574 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation (receiving information)
Number of subjects: 2403
Study 35924574 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement (prioritizing risks)
Number of subjects: 2403
Study 35924574 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership (identifying prevention actions)
Number of subjects: 2403
Study 35924574 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercises
Number of subjects: 2403
Study 35924574 — intervention group
Group type: COMPARATOR
Intervention: Two visits vs. one visit
Number of subjects: 2403